Hermiston TW[Author] - Search Results

Year	Number of Results
1987	1
1990	1
1991	2
1993	2
1994	1
1995	1
1996	4
1997	1
1998	2
2001	3
2002	1
2003	1
2005	4
2006	1
2007	4
2008	6
2009	1
2010	2
2011	2
2012	1
2013	1
2016	1
2021	1
2022	1
2023	2
2024	2

1

Wold WS, Tollefson AE, Hermiston TW. Wold WS, et al. Among authors: hermiston tw. Curr Top Microbiol Immunol. 1995;199 ( Pt 1):237-74. doi: 10.1007/978-3-642-79496-4_13. Curr Top Microbiol Immunol. 1995. PMID: 7555057 Review. No abstract available.

2

Adenovirus proteins that subvert host defenses.

Wold WS, Hermiston TW, Tollefson AE. Wold WS, et al. Among authors: hermiston tw. Trends Microbiol. 1994 Nov;2(11):437-43. doi: 10.1016/0966-842x(94)90801-x. Trends Microbiol. 1994. PMID: 7532531 Review.

3

Allogeneic somatic cell therapy: process development challenges and future opportunities.

Fawaz FS, Hermiston TW, Dinter H. Fawaz FS, et al. Among authors: hermiston tw. Curr Opin Mol Ther. 2010 Aug;12(4):383-5. Curr Opin Mol Ther. 2010. PMID: 20707031 Review.

4

Selective modulation of activated protein C activities by a nonactive site-targeting nanobody library.

Sim DS, Shukla M, Mallari CR, Fernández JA, Xu X, Schneider D, Bauzon M, Hermiston TW, Mosnier LO. Sim DS, et al. Among authors: hermiston tw. Blood Adv. 2023 Jul 11;7(13):3036-3048. doi: 10.1182/bloodadvances.2022008740. Blood Adv. 2023. PMID: 36735416 Free PMC article.

5

Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development.

Hermiston TW, Kirn DH. Hermiston TW, et al. Mol Ther. 2005 Apr;11(4):496-507. doi: 10.1016/j.ymthe.2004.12.004. Mol Ther. 2005. PMID: 15771953 Free article. Review.

6

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.

Hermiston TW, Kuhn I. Hermiston TW, et al. Cancer Gene Ther. 2002 Dec;9(12):1022-35. doi: 10.1038/sj.cgt.7700542. Cancer Gene Ther. 2002. PMID: 12522441 Review.

7

In vitro characterization of CT-001-a short-acting factor VIIa with enhanced prohemostatic activity.

Sim DS, Mallari CR, Teare JM, Feldman RI, Bauzon M, Hermiston TW. Sim DS, et al. Among authors: hermiston tw. Res Pract Thromb Haemost. 2021 Jun 30;5(5):e12530. doi: 10.1002/rth2.12530. eCollection 2021 Jul. Res Pract Thromb Haemost. 2021. PMID: 34263099 Free PMC article.

8

CT-001, a novel fast-clearing factor VIIa, enhanced the hemostatic activity in postpartum samples.

Sim DS, Mallari CR, Hermiston TW, Bae D, Lee S, Allen T, Gilner J, Kim SC, James AH. Sim DS, et al. Among authors: hermiston tw. Blood Adv. 2024 Jan 23;8(2):287-295. doi: 10.1182/bloodadvances.2023011398. Blood Adv. 2024. PMID: 38039512 Free PMC article.

9

Identification and function probing of an antithrombin IIIβ conformation-specific antibody.

Jin Y, Yegneswaran S, Gu JM, Gritzan U, Schönfeld DL, Paz P, Patel C, Dittmer F, Strerath M, Bringmann P, Kauser K, Myles T, Murphy JE, Hermiston TW. Jin Y, et al. Among authors: hermiston tw. J Thromb Haemost. 2016 Feb;14(2):356-65. doi: 10.1111/jth.13198. Epub 2016 Jan 6. J Thromb Haemost. 2016. PMID: 26581031 Free article.

10

CT-001 is a rapid clearing factor VIIa with enhanced clearance and hemostatic activity for the treatment of acute bleeding in non-hemophilia settings.

Sim DS, Mallari CR, Teare JM, Bauzon M, Hermiston TW. Sim DS, et al. Among authors: hermiston tw. Thromb Res. 2022 Jul;215:58-66. doi: 10.1016/j.thromres.2022.05.007. Epub 2022 May 18. Thromb Res. 2022. PMID: 35640516

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

43 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year